These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 14687906)
1. Complex formation between human kallikrein 13 and serum protease inhibitors. Kapadia C; Yousef GM; Mellati AA; Magklara A; Wasney GA; Diamandis EP Clin Chim Acta; 2004 Jan; 339(1-2):157-67. PubMed ID: 14687906 [TBL] [Abstract][Full Text] [Related]
2. The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids. Yousef GM; Kapadia C; Polymeris ME; Borgono C; Hutchinson S; Wasney GA; Soosaipillai A; Diamandis EP Biochim Biophys Acta; 2003 Jul; 1628(2):88-96. PubMed ID: 12890555 [TBL] [Abstract][Full Text] [Related]
3. Human kallikrein 13 involvement in extracellular matrix degradation. Kapadia C; Ghosh MC; Grass L; Diamandis EP Biochem Biophys Res Commun; 2004 Oct; 323(3):1084-90. PubMed ID: 15381110 [TBL] [Abstract][Full Text] [Related]
4. Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay. Kapadia C; Chang A; Sotiropoulou G; Yousef GM; Grass L; Soosaipillai A; Xing X; Howarth DH; Diamandis EP Clin Chem; 2003 Jan; 49(1):77-86. PubMed ID: 12507963 [TBL] [Abstract][Full Text] [Related]
5. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. Scorilas A; Borgoño CA; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP J Clin Oncol; 2004 Feb; 22(4):678-85. PubMed ID: 14966091 [TBL] [Abstract][Full Text] [Related]
6. Functional proteomics of kallikrein-related peptidases in ovarian cancer ascites fluid. Oikonomopoulou K; Batruch I; Smith CR; Soosaipillai A; Diamandis EP; Hollenberg MD Biol Chem; 2010 Apr; 391(4):381-90. PubMed ID: 20180649 [TBL] [Abstract][Full Text] [Related]
7. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Yousef GM; Polymeris ME; Grass L; Soosaipillai A; Chan PC; Scorilas A; Borgoño C; Harbeck N; Schmalfeldt B; Dorn J; Schmitt M; Diamandis EP Cancer Res; 2003 Jul; 63(14):3958-65. PubMed ID: 12873991 [TBL] [Abstract][Full Text] [Related]
8. alpha2-macroglobulin and C1-inactivator are plasma inhibitors of human glandular kallikrein. Heeb MJ; España F Blood Cells Mol Dis; 1998 Dec; 24(4):412-9. PubMed ID: 9851894 [TBL] [Abstract][Full Text] [Related]
9. Purification of human kallikrein 6 from biological fluids and identification of its complex with alpha(1)-antichymotrypsin. Hutchinson S; Luo LY; Yousef GM; Soosaipillai A; Diamandis EP Clin Chem; 2003 May; 49(5):746-51. PubMed ID: 12709365 [TBL] [Abstract][Full Text] [Related]
10. Purification of enzymatically active kallikrein hK2 from human seminal plasma. Frenette G; Deperthes D; Tremblay RR; Lazure C; Dubé JY Biochim Biophys Acta; 1997 Feb; 1334(1):109-15. PubMed ID: 9042371 [TBL] [Abstract][Full Text] [Related]
11. Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. Luo LY; Grass L; Howarth DJ; Thibault P; Ong H; Diamandis EP Clin Chem; 2001 Feb; 47(2):237-46. PubMed ID: 11159772 [TBL] [Abstract][Full Text] [Related]
12. Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids. Shaw JL; Grass L; Sotiropoulou G; Diamandis EP Clin Biochem; 2007 Jan; 40(1-2):104-10. PubMed ID: 17045982 [TBL] [Abstract][Full Text] [Related]
13. Inhibition profiles of human tissue kallikreins by serine protease inhibitors. Luo LY; Jiang W Biol Chem; 2006 Jun; 387(6):813-6. PubMed ID: 16800745 [TBL] [Abstract][Full Text] [Related]
14. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids. Lövgren J; Valtonen-André C; Marsal K; Lilja H; Lundwall A J Androl; 1999; 20(3):348-55. PubMed ID: 10386814 [TBL] [Abstract][Full Text] [Related]
15. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Borgoño CA; Grass L; Soosaipillai A; Yousef GM; Petraki CD; Howarth DH; Fracchioli S; Katsaros D; Diamandis EP Cancer Res; 2003 Dec; 63(24):9032-41. PubMed ID: 14695222 [TBL] [Abstract][Full Text] [Related]
16. Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum. Grauer LS; Finlay JA; Mikolajczyk SD; Pusateri KD; Wolfert RL J Androl; 1998; 19(4):407-11. PubMed ID: 9733142 [TBL] [Abstract][Full Text] [Related]
17. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. Michael IP; Sotiropoulou G; Pampalakis G; Magklara A; Ghosh M; Wasney G; Diamandis EP J Biol Chem; 2005 Apr; 280(15):14628-35. PubMed ID: 15713679 [TBL] [Abstract][Full Text] [Related]
18. Structural Studies on the Inhibitory Binding Mode of Aromatic Coumarinic Esters to Human Kallikrein-Related Peptidase 7. Hanke S; Tindall CA; Pippel J; Ulbricht D; Pirotte B; Reboud-Ravaux M; Heiker JT; Sträter N J Med Chem; 2020 Jun; 63(11):5723-5733. PubMed ID: 32374603 [TBL] [Abstract][Full Text] [Related]
20. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. Schapira M; Scott CF; Colman RW J Clin Invest; 1982 Feb; 69(2):462-8. PubMed ID: 6173399 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]